Company Description
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Dr. Bharatt M. Chowrira J.D., Ph.D. |
Contact Details
Address: 6 Tide Street, Suite 400 Boston, Massachusetts 02210 United States | |
| Phone | 617-482-2333 |
| Website | puretechhealth.com |
Stock Details
| Ticker Symbol | PRTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782999 |
| CUSIP Number | 746237106 |
| ISIN Number | US7462371060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daphne Zohar | Founder, Senior Advisor and Board Observer |
| Dr. Robert S. Langer Jr., Ph.D. | Co-Founder and Non-Executive Director |
| Dr. Eric Elenko Ph.D. | President, Chief Innovation and Strategy Officer |
| Dr. David R. Elmaleh Ph.D. | Co-Founder and Senior Advisor |
| Allison Mead Talbot | Head of Communications and Investor Relations |
| Spencer Ball | Senior Vice President of Human Resources |
| Aleksandra Filipovic M.D., Ph.D. | Head of Oncology |
| Cheryl Murphy Ph.D. | Head of Grants Management and Strategy |
| Anita Terpstra J.D., Ph.D. | Senior Vice President and Head of Intellectual Property |
| Dilip Kodira | Head of Data Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2024 | SC TO-I | Filing |
| Apr 25, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Mar 19, 2024 | SC TO-C | Filing |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Mar 18, 2024 | 6-K | Report of foreign issuer |
| Mar 4, 2024 | 6-K | Report of foreign issuer |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 5, 2024 | 6-K | Report of foreign issuer |